Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Conditions

Major Depressive Disorder

Keywords

Depressive Disorder, Major, Melancholia, Involutional, Depression, Involutional

Brief summary

To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.

Sigal Zilcha‐Mano, Xuemei Wang, Dalia Wajsbrot, Matthieu Boucher, Stuart A. Fine et al. (6 authors)

Journal of Clinical Psychopharmacology2021-06-291 citations

10.1097/jcp.0000000000001435

Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.

McIntyre RS, Fayyad R, Mackell JA, Boucher M.

2016-01-133 citations

10.1185/03007995.2015.1136603

A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d

Roger S. McIntyre, Rana Fayyad, Christine J. Guico‐Pabia, Matthieu Boucher

The Primary Care Companion For CNS Disorders2015-06-0411 citations

10.4088/pcc.14m01741

Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.

Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA.

2015-03-267 citations

10.1185/03007995.2015.1020365

Interventions

DRUGDVS-233 SR

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

No

Inclusion criteria

* Outpatients * Sexually active women participating in the study must use a medically acceptable form of contraception * Subjects must have a primary diagnosis of major depressive disorder

Exclusion criteria

* Treatment with DVS-233 SR at any time in the past * Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1 * Known hypersensitivity to venlafaxine (IR or ER)

Outcome results

None listed